Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel in Advanced Gastric/GEJ Cancer
NCT02251951Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Sep 2012
- Primary completion
- Jun 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Hellenic Oncology Research Group. Primary endpoint: Overall Response Rate up to 108 weeks. Started Sep 2012; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02251951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251951.